Pyrazinamide

Pyrazinamide should always be administered with other effective antituberculous drugs. It is administered for the initial 2 months of a 6-month or longer treatment regimen for drug-susceptible patients. Patients who are known or suspected to have drug-resistant disease should be treated with regimens individualized to their situation.

Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.

Pyrazinamide is contraindicated in persons: with severe hepatic damage. who have shown hypersensitivity to it. with acute gout.

Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.

Patients started on pyrazinamide should have baseline serum uric acid and liver function determinations. Those patients with preexisting liver disease or those at increased risk for drug related hepatitis (e.g., alcohol abusers) should be followed closely. Pyrazinamide should be discontinued and not be resumed if signs of hepatocellular damage or hyperuricemia accompanied by an acute gouty arthritis appear.

Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.

General Fever, porphyria and dysuria have rarely been reported. Gout (see PRECAUTIONS). Gastrointestinal The principal adverse effect is a hepatic reaction (see WARNINGS). Hepatotoxicity appears to be dose related, and may appear at any time during therapy. GI disturbances including nausea, vomiting and anorexia have also been reported.

Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.

86 products from 50 makers in the NepalDoc medicine catalog use this generic:

Showing 30 of 86 catalog products. Search the full catalog in the app.

Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.

Store at 20° to 25°C (68° to 77°F).

Storage information from the U.S. FDA-approved label.